Uncovering combination therapies for immune-mediated inflammatory diseases through systems biology analysis on longitudinal patient data.
While targeted therapies have reshaped the clinical management of immune-mediated inflammatory diseases (IMIDs), primary non-response remains a major obstacle for many patients. Combining two targeted therapies is an emerging strategy to overcome this therapeutic ceiling, but the number of possible drug pairs makes pri...